New research offers hope for improving the lives of those living with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, conditions that affect as many as three million Americans. Matt Baker, who has lived with ulcerative colitis since college, describes the often crippling pain associated with the disease. While medications helped initially, Baker eventually enrolled in a clinical trial at University Gastroenterology to test Ozanimod, a once-daily pill that reduces intestinal inflammation. Since starting the trial, Baker has experienced significant improvements in his quality of life, with fewer and milder flare-ups.
Keep Reading
Add A Comment